Swiss contract drug maker Lonza struck a deal with California-based biopharmaceutical company Humanigen to expand manufacturing capacity for Humanigen’s lenzilumab, a drug candidate in late-stage clinical trials for COVID-19. Lenzilumab is in phase III clinical trials to determine whether the drug can prevent and treat an immune hyper-response in COVID-19 patients called “cytokine storm”, the companies said in a statement on Tuesday. Source: Reuters 15/9/2020